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Over the last two decades, awareness of enterococci as
important multidrug-resistant (MDR) nosocomial pathogens
has increased [1,2]. Enterococci are now among the leading
healthcare-associated pathogens worldwide [3–7]. Enterococ-
cus faecalis and Enterococcus faecium remain the dominant
species in clinical infections, although their relative contribu-
tions have changed over the years. The ratio of E. faecalis to
E. faecium in systemic infections has now approached 1:1 in
many countries [3–5]. Importantly, the absolute and relative
increase in E. faecium infections has been associated with
acquired resistance to important anti-enterococcal agents
such as ampicillin, aminoglycosides and vancomycin [3,8].
Molecular epidemiological studies and population structure
analyses suggest that the emergence of E. faecalis and E. fae-
cium as major nosocomial pathogens has resulted from the
evolutionary development of speciﬁc hospital-associated lin-
eages or clonal complexes in which antimicrobial resistance
and virulence determinants have accumulated [9–11].
During the last decade, risk factors for colonization and
bacteraemia have been identiﬁed and include underlying dis-
eases, antibiotic use, noncompliance with infection control
measures and colonization pressure [12–14]. Moreover,
molecular evidence with respect to how gastrointestinal col-
onization with MDR enterococci can be promoted by anti-
biotic-induced mucosal innate immunity deﬁcits has recently
been provided [15]. Notably, early and appropriate anti-
microbial therapy of bacteraemia caused by MDR entero-
cocci improves patient survival [14]. Thus, the changing
epidemiology of enterococcal infections remains a true chal-
lenge in clinical diagnostic microbiology, both for infection
control and antimicrobial treatment.
This special theme section on enterococcal infections has
been stimulated by the collaborative efforts of many co-
authoring researchers during the ongoing ACE (Approaches
to Control multi-resistant Enterococci) project, funded by
the Sixth Framework Programme of the European Union
(http://www.aceproject.eu/project_outline.php). In this special
section, the mechanisms that may have promoted the transi-
tion of enterococci from human gastrointestinal commensals
to major nosocomial pathogens are reviewed, as well as the
latest insights concerning anti-enterococcal therapy. Recent
genomic insights into the evolution of E. faecalis and E. fae-
cium are reviewed by van Schaik and Willems [16]. Whole-
genome sequencing and comparative genomic analysis have
revealed large intra-species diversity also within clonally
related strains. Until recently, there has been a relative lack
of genome information in enterococci compared to other
human pathogens. However, in 2009, more than 20 draft gen-
ome sequences of E. faecalis and E. faecium were deposited in
public databases, providing new opportunities for reﬁning our
understanding of Enterococcus. Sava et al. [17] summarize our
current knowledge of putative virulence factors in E. faecalis
and E. faecium and the identiﬁcation of targets of protective
immune responses. Subsequently, Hegstad and co-workers
provide an update on mobile genetic elements in enterococci
and their contribution to the spread of antimicrobial resis-
tance and associated virulence determinants [18]. Recent
developments in the molecular epidemiology and typing of
enterococcal plasmids are also addressed. Finally, Arias et al.
[19] review the clinical challenges faced with respect to anti-
microbial treatment of infections by MDR enterococci. Cur-
rent therapeutic alternatives of severe MDR enterococcal
infections remain to be based on empirical observations and
extrapolation from in vitro and animal data, emphasizing the
critical need for clinical studies that evaluate new therapies.
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